IBT
AERI

International Biotechnology Trust’s Aerie Pharmaceuticals AERI Stock Holding History

International Biotechnology Trust’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-151,117
Closed -$7.18M – 69
2019
Q1 		$7.18M Buy
151,117
+136,117
+907% +$5.99M 2.65% 14
2018
Q4 		$425K Sell
15,000
-110,179
-88% -$5.17M 0.26% 43
2018
Q3 		$5.91M Buy
125,179
+110,400
+747% +$7.1M 2.81% 13
2018
Q2 		$998K Hold
14,779
– – 0.38% 46
2018
Q1 		$802K Hold
14,779
– – 0.31% 57
2017
Q4 		$883K Hold
14,779
– – 0.31% 56
2017
Q3 		$718K Sell
14,779
-79,043
-84% -$4.31M 0.28% 52
2017
Q2 		$4.93M Buy
93,822
+78,822
+525% +$3.67M 1.87% 17
2017
Q1 		$680K Sell
15,000
-123,000
-89% -$5.49M 0.26% 58
2016
Q4 		$5.21M Buy
+138,000
New +$5.22M 2.35% 15

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

International Biotechnology Trust's AERI Position: Q2 2019 in Review

International Biotechnology Trust sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 151,117 shares — an estimated $7.18M sold.

International Biotechnology Trust first reported a position in AERI in Q4 2016 and held it in 10 quarters. The position peaked at $7.18M in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • International Biotechnology Trust reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • International Biotechnology Trust sold 151,117 Aerie Pharmaceuticals shares in Q2 2019, an estimated $7.18M.
  • International Biotechnology Trust first reported a position in Aerie Pharmaceuticals in Q4 2016 and held it in 10 quarters.
  • International Biotechnology Trust's Aerie Pharmaceuticals position peaked at $7.18M in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on International Biotechnology Trust's 13F filing for Q2 2019, filed 14 Aug 2019.